Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.

Idiopathic Intracranial Hypertension Clinical Trial

— IIH:DT  

Official title:

Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02017444
• Other study ID #: RG_13-022
• Secondary ID: 2013-003643-31MR
• Status: Completed
• Phase: Phase 2
• Start date: April 25, 2014
• Est. completion date: December 19, 2016

Study information

• Verified date: September 2021
• Source: University of Birmingham
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Assessing the safety and effectiveness of a 11-βhydroxysteroid dehydrogenase type 1 inhibitor (AZD4017), in a placebo controlled trial, in acute idiopathic intracranial hypertension (IIH) IIH is a condition of young, overweight women with characteristic raised intracranial pressure (pressure around the brain) leading to papilloedema (swelling of the nerve supplying the eye), visual loss and headaches. Medical literature (Cochrane review) demonstrates there is little evidence for the treatments used for IIH. Weight control appears the most effective method of improving symptoms but weight loss is difficult to maintain. 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an enzyme which regulates local steroid levels and our previous research suggests it may influence the production of brain fluid(cerebrospinal fluid or CSF). 11β-HSD1 levels fall with weight loss and this is associated with with decreased intracranial pressure. Our primary outcome is to determine whether AZD4017, an inhibitor of 11β-HSD1, will reduce the pressure in the brain and as a consequence improve IIH. Patients are eligible to enter the study if they are between 18-55 years old with acute (<6 months) IIH, signs of active disease (papilloedema and raised CSF pressure (>25 cmH20)), no other major illnesses and have no plans for pregnancy during the study period. This is an MRC funded single centre, phase II, double-blinded, randomised control drug trial. It will be conducted at the University Hospital Birmingham and the University of Birmingham will act as Sponsor. Eligible participants will be randomly assigned to AZD4017 or a placebo ('dummy' with no active drug) for 3 months with a follow up a month later. Investigations during the study will include bloods, urine samples, pregnancy tests, lumbar punctures, DXA scans and small fat/skin biopsies. Participants will benefit from increased monitoring and a potential improvement in their condition. We hypothesise that specific inhibition of 11β-HSD1 will decrease intracranial pressure and consequently treat patients with IIH, thus opening a new and entirely novel therapeutic avenue.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: December 19, 2016
• Est. primary completion date: December 19, 2016
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Provision of informed consent prior to any study specific procedures.
• Female patients between 18 and 55 years
• Diagnosis of IIH by the Modified Dandy criteria1 with:

1. acute (<6 months),

2. active disease (papilloedema (Frisen grade greater than or equal to 1),

3. significantly raised ICP > 25cmH2O)

4. normal brain imaging during previous routine diagnostic work up (evaluated by either magnetic resonance venography or computerised tomography with venography).

• Patients must be willing to use one form of highly effective non-hormonal

contraception. This would include:

1. a vasectomised partner (sole partner) or tubal occlusion or

2. copper containing IUD - all of which should be used in addition to a diaphragm or cervical/vault caps with barrier contraceptive (condom or spermicidal foam/gel/film/suppository)

3. true abstinence (when this is in line with the preferred and usual lifestyle of the subject. Women should have been stable on their chosen method of birth control for a minimum of 2 months before entering the trial. Patients must agree to undergo a ß-hCG pregnancy test and urine dipstick test at screening and urine dipstick testing at all trial visits (including the final follow up visit 4 weeks after discontinuation of study treatment). Note: the use of contraception and pregnancy testing would not be required if the screening LH/FSH levels demonstrate the patient is post-menopausal.

• Participants are able to continue other medications to treat their IIH e.g. acetazolamide, diuretics but this dose must remain fixed throughout the study.
• Patients who take aspirin therapy will be asked to discontinue aspirin 3 days prior to fat and skin biopsy if clinically safe to do so.
• Placebo treatment for the duration of the study must not be considered detrimental to the patient.
• Must be able to understand the consent form and comply with study requirements.

Exclusion Criteria:

• Optic nerve sheath fenestration.
• Patients who undergo CSF shunt insertion (which is not elective or pre- planned) during the study, as a result of deterioration will be withdrawn from the study.
• Abnormal neurological examination (aside from papilloedema and consequent visual loss or VI nerve palsy).
• Subjects with a secondary cause of raised intracranial pressure will be excluded (venous thrombosis, anaemia, drug causes (lithium, vitamin A, tetracycline or others deems responsible for the condition).
• Abnormal CSF contents (except for that compatible with a traumatic LP).
• Unable to perform a visual field reliably.

General Exclusion Criteria:

• Positive hCG or urine dipstick pregnancy test or planning to conceive in the 4 study months.
• Have eGFR calculated by MDRD equation of <60ml/min/1.73m2.
• Have any endocrine disorder, e.g. thyroid dysfunction. This excludes PCOS where there is a known association to IIH.
• Suspicion of or known Gilbert's disease.
• CK >2 x ULN on 2 consecutive measurements.
• ALT and/or AST >2 x ULN.
• ALP > ULN.
• Bilirubin (total) > 2 x ULN.
• Must not have donated blood within 2 months of screening and avoid further donations for 4 months following the study.
• Patient is, at the time of signing the informed consent, a user of recreational or illicit drugs (including marijuana) or has had a recent history (within the last year) of drug or alcohol abuse or dependence.
• Pregnant or breastfeeding mothers, unless willing to discontinue breastfeeding by the baseline visit.
• Have uncontrolled systemic hypertension (BP >160/90), on 3 successive measurements on the morning of the screening visit.
• Are receiving systemic (including vaginal/rectal) glucocorticoid treatment at the time of the screening visit. Note: Topical and inhaled are acceptable
• Are taking any hormone-based medication, including hormone contraceptives, at the time of screening.
• Are taking probenecid at the time of the screening visit.
• Have any screening laboratory abnormality that, in the investigator's judgement, is considered to be clinically significant or any screening laboratory value which is outside the Sponsor specified ranges at screening; testing may be repeated but must be resolved prior to the baseline visit.
• History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation or will influence the results .
• History or presence of significant gastrointestinal, hepatic , or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IP as judged by the investigator.
• Have been involved in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
• Have participated in any other interventional study within 1 month prior to the screening visit. Participation in the IIH National database or other observational studies will not prevent enrolment to this study.
• Previous randomisation for treatment in the present study

Related Conditions & MeSH terms

• Hypertension
• Idiopathic Intracranial Hypertension
• Intracranial Hypertension
• Pseudotumor Cerebri

Intervention

Drug:
• AZD4017

Other:
• Placebo
Matched placebo (matched to AZD4017 arm)

Locations

Country	Name	City	State
United Kingdom	University Hospital Birmingham (Queen Elizabeth Hospital)	Birmingham	West Midlands

Sponsors (1)

Lead Sponsor	Collaborator
University of Birmingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Intracranial Pressure	ICP measured by lumbar puncture in cmCSF as the change from week 0 and week 12 of treatment, measured at baseline and week 12	12 weeks
Secondary	Tinnitus	The temporal change in IIH symptoms (presence or absence of tinnitus), measured at baseline and week 12	12 weeks
Secondary	Anthropometric Measurements (BMI)	The temporal change in Body Mass Index (in kg/m^2) over 12 weeks of treatment, measured at baseline and week 12	12 weeks
Secondary	Visual Loss	The temporal change in IIH symptoms (presence or absence of visual loss, measured at baseline and week 12	12 weeks
Secondary	Diplopia	The temporal change in IIH symptoms (presence or absence of diplopia, measured at baseline and week 12	12 weeks
Secondary	Visual Obscuration	The temporal change in IIH symptoms (presence or absence of visual obscuration, measured at baseline and week 12	12 weeks
Secondary	Headache	The temporal change in IIH symptoms (presence or absence of headache, measured at baseline and week 12	12 weeks
Secondary	Visual Acuity	The temporal change in IIH visual function in both eyes (measured by LogMAR (log of the minimum angle of resolution) chart to assess visual acuity, between the baseline to week 12, measured at baseline and week 12	12 weeks
Secondary	Papilloedema	The temporal change in papilloedema (evaluated at the end of trial follow up using stereoscopic fundus photographs by masked neuro-ophthalmologists to grade the images according to Frisen classification) measured at baseline and week 12. There are 6 grades, 0-5, 5 being the worst.; The modified Frisén scale for grading papilledema using fundus photography is as follows: Grade 1 - C-Shaped halo with a temporal gap; Grade 2 - The halo becomes circumferential; Grade 3 - Loss of major vessels as they leave the disc; Grade 4 - Loss of major vessels on the disc; Grade 5 - Criteria of Grade IV + partial or total obscuration of all vessels on the disc; For further details see e.g. Scott, C.J., et al., Diagnosis and grading of papilledema in patients with raised intracranial pressure using optical coherence tomography vs clinical expert assessment using a clinical staging scale. Arch. Ophthalmol, 2010. 128(6): p. 705-711.	12 weeks
Secondary	Headache-associated Disability	The change in headache associated disability through the headache impact test-6 score (HIT 6), measured at baseline and week 12. This is scored 11-66 with higher scores indicating worse headache.	12 weeks
Secondary	Adverse Events	The safety and tolerability profile of AZD4017 in female patients with IIH through adverse event reporting and safety bloods.	16 weeks
Secondary	Serious Adverse Events	The safety and tolerability profile of AZD4017 in female patients with IIH through adverse event reporting and safety bloods.	16 weeks
Secondary	OCT Total Average Retinal Nerve Fibre Layer Thickness (µm)	The temporal change in OCT Total average retinal nerve fibre layer thickness (µm), measured at baseline and week 12	12 weeks
Secondary	Visual Field Mean Deviation	The temporal change in IIH visual function in both eyes using automated perimetry (Humphrey 24-2 central threshold) to measure the visual field mean deviation between the baseline to week 12	12 weeks
Secondary	Log Contrast Sensitivity	The temporal change in IIH visual function in both eyes using a Pelli-Robson chart to evaluate log contrast sensitivity between the baseline to week 12	12 weeks